---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022513"
form_type: "8-K"
ticker: "DXR"
cik: "0000027367"
company_name: "DAXOR CORP"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:33:04.928064+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer

## Summary
- FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.
- Device provides results 3x faster, weighs 7 lbs, delivers lab-grade precision.
- Clinical data: BVA-guided care reduced heart failure mortality by 86% (p<0.001), ICU mortality by 66%.
- Over 75,000 tests shipped; developed under U.S. Army/DHA contract.
- Management expects high demand driven by speed, simplicity, precision.

## SEC filing metadata
- accession: 0001641172-25-022513
- form_type: 8-K
- ticker: DXR
- cik: 0000027367
- company_name: DAXOR CORP
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/27367/000164117225022513/0001641172-25-022513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/27367/000164117225022513/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022513
- JSON: https://secwatch.observer/filing/0001641172-25-022513.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.